Business
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter".
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: \"Cannabinoids, The Heart of the Matter\"\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: \"Cannabinoids, The Heart of the Matter\"\nPR Newswire\nLAS VEGAS, Aug. 2, 2018\n\n\n\nThis pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research.\n\n\n\nLAS VEGAS, Aug. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in \"Cannabinoids, the Heart of the Matter\". The link to the article is found at http://dx.doi.org/10.1161/JAHA.118.009099. While there have been recent studies supporting the use of cannabinoids for seizure disorders, most people and many scientists are not aware of the potential uses for cannabinoids in treating cardiac hypertrophy and other heart diseases.\n\n\n \n \n\n \n\"With the recent FDA approval of GW Pharma's cannabinoid-based drug, Epidiolex, people are becoming more aware that cannabinoid-based therapies can have significant medical benefits for patients with seizures caused by Lennox-Gastaut or Dravet Syndrome,\" explains Dr. Small-Howard, \"but we wanted to bring attention to the potential life-saving applications of cannabinoids for the treatment of heart conditions through the manipulation of specific-cannabinoid sensitive receptors.\"...